In preclinical models, it has been shown that, by regulating the tumour microenvironment, they affect the reduction of CD8+ lymphocytes in the systemic circulation by activating their apoptosis, which occurs in the liver, directly leading to a reduced benefit of immunotherapy [14]. Here, CD8A is linked to neoplasm.